Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma.
Joshua RichterPeggy L LinViviana Garcia-HortonPatricia GuyotErin SinghZheng-Yi ZhouMark SievertRiley TaijiPublished in: Cancer medicine (2023)
These results support Isa-Kd as an efficacious treatment for early relapse in non-lenalidomide refractory patients.